Nothing said here yet.
to join the conversation.
| Privitera SalvatoreChief Technical Officer | Sell | 4,519 | $271.1K | Wed, Sep 23 |
| GROVES REGINA EDirector | Sell | 5,313 | $288.1K | Fri, Sep 11 |
| Privitera SalvatoreChief Technical Officer | Sell | 3,657 | $201.1K | Tue, Sep 8 |
| Privitera SalvatoreChief Technical Officer | Sell | 7,763 | $407.6K | Wed, Sep 2 |
| Dahlquist Karl S.Chief Legal Officer | Sell | 9,370 | $458.1K | Mon, Aug 24 |
| Gilbert Cisneros | Sell | $8.0K | Tue, Sep 29 | Fri, Oct 9 |
| Gilbert Cisneros | Buy | $8.0K | Thu, Aug 20 | Fri, Sep 4 |
AtriCure’s fair value price target has shifted from about US$51.67 to about US$54.89, which reflects modest fine tuning in analyst models rather than a wholesale reset.
AtriCure has delivered a strong run over the past year, and the latest close at US$60.77 puts a clear spotlight on what investors are paying for its sales.
AtriCure (ATRC) has drawn fresh attention after its shares closed at US$60.77, with recent returns over the past month and past 3 months sharply outpacing many healthcare peers.
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Privitera executed the sale under a pre-established Rule 10b5-1 trading plan.
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
AtriCure (ATRC) drew fresh investor attention after filing two shelf registrations related to employee stock ownership offerings, covering up to 2,250,000 common shares and approximately US$78.8 million in potential issuance capacity.